Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke

Kristian P. Doyle, Tao Yang, Nikola S. Lessov, Thomas M. Ciesielski, Susan L. Stevens, Roger P. Simon, Jeffrey S. King, Mary Stenzel-Poore

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Osteopontin (OPN), a large secreted glycoprotein with an arginine, glycine, aspartate (RGD) motif, can bind and signal through cellular integrin receptors. We have shown previously that OPN enhances neuronal survival in the setting of ischemia. Here, we sought to increase the neuroprotective potency of OPN and improve the method of delivery with the goal of identifying a treatment for stroke in humans. We show that thrombin cleavage of OPN improves its ability to ligate integrin receptors and its neuroprotective capacity in models of ischemia. Thrombin-cleaved OPN is a twofold more effective neuroprotectant than the untreated molecule. We also tested whether OPN could be administered intranasally and found that it is efficiently targeted to the brain via intranasal delivery. Furthermore, intranasal administration of thrombin-treated OPN confers protection against ischemic brain injury. Osteopontin mimetics based on the peptide sequences located either N or C terminal to the thrombin cleavage site were generated and tested in models of ischemia. Treatment with successively shorter N-terminal peptides and a phosphorylated C-terminal peptide provided significant neuroprotection against ischemic injury. These findings show that OPN mimetics offer promise for development into new drugs for the treatment of stroke.

Original languageEnglish (US)
Pages (from-to)1235-1248
Number of pages14
JournalJournal of Cerebral Blood Flow and Metabolism
Volume28
Issue number6
DOIs
StatePublished - Jun 30 2008

Fingerprint

Intranasal Administration
Osteopontin
Stroke
Peptides
Thrombin
Ischemia
Integrins
Neuroprotection
Neuroprotective Agents
Glycine
Brain Injuries
Glycoproteins
Therapeutics

Keywords

  • Integrin
  • Nasal administration
  • Osteopontin
  • RGD
  • Stroke

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. / Doyle, Kristian P.; Yang, Tao; Lessov, Nikola S.; Ciesielski, Thomas M.; Stevens, Susan L.; Simon, Roger P.; King, Jeffrey S.; Stenzel-Poore, Mary.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 28, No. 6, 30.06.2008, p. 1235-1248.

Research output: Contribution to journalArticle

Doyle, Kristian P. ; Yang, Tao ; Lessov, Nikola S. ; Ciesielski, Thomas M. ; Stevens, Susan L. ; Simon, Roger P. ; King, Jeffrey S. ; Stenzel-Poore, Mary. / Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. In: Journal of Cerebral Blood Flow and Metabolism. 2008 ; Vol. 28, No. 6. pp. 1235-1248.
@article{bdf1af24617c42b1a545b335a8f61690,
title = "Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke",
abstract = "Osteopontin (OPN), a large secreted glycoprotein with an arginine, glycine, aspartate (RGD) motif, can bind and signal through cellular integrin receptors. We have shown previously that OPN enhances neuronal survival in the setting of ischemia. Here, we sought to increase the neuroprotective potency of OPN and improve the method of delivery with the goal of identifying a treatment for stroke in humans. We show that thrombin cleavage of OPN improves its ability to ligate integrin receptors and its neuroprotective capacity in models of ischemia. Thrombin-cleaved OPN is a twofold more effective neuroprotectant than the untreated molecule. We also tested whether OPN could be administered intranasally and found that it is efficiently targeted to the brain via intranasal delivery. Furthermore, intranasal administration of thrombin-treated OPN confers protection against ischemic brain injury. Osteopontin mimetics based on the peptide sequences located either N or C terminal to the thrombin cleavage site were generated and tested in models of ischemia. Treatment with successively shorter N-terminal peptides and a phosphorylated C-terminal peptide provided significant neuroprotection against ischemic injury. These findings show that OPN mimetics offer promise for development into new drugs for the treatment of stroke.",
keywords = "Integrin, Nasal administration, Osteopontin, RGD, Stroke",
author = "Doyle, {Kristian P.} and Tao Yang and Lessov, {Nikola S.} and Ciesielski, {Thomas M.} and Stevens, {Susan L.} and Simon, {Roger P.} and King, {Jeffrey S.} and Mary Stenzel-Poore",
year = "2008",
month = "6",
day = "30",
doi = "10.1038/jcbfm.2008.17",
language = "English (US)",
volume = "28",
pages = "1235--1248",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke

AU - Doyle, Kristian P.

AU - Yang, Tao

AU - Lessov, Nikola S.

AU - Ciesielski, Thomas M.

AU - Stevens, Susan L.

AU - Simon, Roger P.

AU - King, Jeffrey S.

AU - Stenzel-Poore, Mary

PY - 2008/6/30

Y1 - 2008/6/30

N2 - Osteopontin (OPN), a large secreted glycoprotein with an arginine, glycine, aspartate (RGD) motif, can bind and signal through cellular integrin receptors. We have shown previously that OPN enhances neuronal survival in the setting of ischemia. Here, we sought to increase the neuroprotective potency of OPN and improve the method of delivery with the goal of identifying a treatment for stroke in humans. We show that thrombin cleavage of OPN improves its ability to ligate integrin receptors and its neuroprotective capacity in models of ischemia. Thrombin-cleaved OPN is a twofold more effective neuroprotectant than the untreated molecule. We also tested whether OPN could be administered intranasally and found that it is efficiently targeted to the brain via intranasal delivery. Furthermore, intranasal administration of thrombin-treated OPN confers protection against ischemic brain injury. Osteopontin mimetics based on the peptide sequences located either N or C terminal to the thrombin cleavage site were generated and tested in models of ischemia. Treatment with successively shorter N-terminal peptides and a phosphorylated C-terminal peptide provided significant neuroprotection against ischemic injury. These findings show that OPN mimetics offer promise for development into new drugs for the treatment of stroke.

AB - Osteopontin (OPN), a large secreted glycoprotein with an arginine, glycine, aspartate (RGD) motif, can bind and signal through cellular integrin receptors. We have shown previously that OPN enhances neuronal survival in the setting of ischemia. Here, we sought to increase the neuroprotective potency of OPN and improve the method of delivery with the goal of identifying a treatment for stroke in humans. We show that thrombin cleavage of OPN improves its ability to ligate integrin receptors and its neuroprotective capacity in models of ischemia. Thrombin-cleaved OPN is a twofold more effective neuroprotectant than the untreated molecule. We also tested whether OPN could be administered intranasally and found that it is efficiently targeted to the brain via intranasal delivery. Furthermore, intranasal administration of thrombin-treated OPN confers protection against ischemic brain injury. Osteopontin mimetics based on the peptide sequences located either N or C terminal to the thrombin cleavage site were generated and tested in models of ischemia. Treatment with successively shorter N-terminal peptides and a phosphorylated C-terminal peptide provided significant neuroprotection against ischemic injury. These findings show that OPN mimetics offer promise for development into new drugs for the treatment of stroke.

KW - Integrin

KW - Nasal administration

KW - Osteopontin

KW - RGD

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=44349100890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349100890&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2008.17

DO - 10.1038/jcbfm.2008.17

M3 - Article

C2 - 18364727

AN - SCOPUS:44349100890

VL - 28

SP - 1235

EP - 1248

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 6

ER -